Physician profile
Vesna Simic
NPI 1912041468
$3,802.08
in general payments reported to CMS, 2019-2025
19 companies · $648 in 2025
The $648 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $232 · 2021: $963 · 2022: $717 · 2023: $256 · 2024: $616 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $785.15 | 2022-2025 | Infuse, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $497.38 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $352.39 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $328.12 | 2019-2021 | |
| Alcon Vision LLC | $309.10 | 2021-2025 | Tryptyr, Dailies Total1, Total30 |
| Johnson & Johnson Vision Care, INC. | $276.71 | 2021-2024 | Acuvue |
| Horizon Therapeutics Plc | $229.74 | 2021-2022 | |
| Coopervision INC. | $186.33 | 2019-2025 | Paragon Crt, Myday Contact Lens, Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $139.49 | 2025 | Xdemvy |
| Lkc Technologies, INC. | $131.26 | 2025 | |
| Dompe US, INC. | $120.16 | 2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $95.45 | 2021 | |
| Shire North American Group INC | $83.60 | 2019 | |
| Visioneering Technologies, INC. | $82.91 | 2019 | |
| Sun Pharmaceutical Industries INC. | $76.23 | 2019-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $41.14 | 2019-2024 | |
| Quidel Corporation | $28.86 | 2020 | |
| Oyster Point Pharma, INC. | $22.91 | 2022 | |
| Allergan, INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vesna Simic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.